Alcidion Group (ALC) AGM 2025 summary

Opening remarks and agenda

• Meeting opened with acknowledgment of traditional custodians and confirmation of quorum, with directors, CEO, CFO, company secretary, and external auditor present.

• Agenda included Chair's address, CEO presentation, formal business, and Q&A.

Financial performance review

• FY2025 revenue reached AUD 40.8 million, up 10% year-on-year, with 63% from the UK and 37% from ANZ.

• Annual recurring revenue was AUD 28.5 million as of June 30, 2025, up 31% year-on-year.

• Underlying EBITDA improved to AUD 5.1 million, an AUD 8.5 million improvement, with positive operating cash flow of AUD 5.8 million.

• Year-end cash was AUD 17.7 million, with no debt, and AUD 73.8 million in new contract value secured.

• Entering FY26 with AUD 34 million in contracted revenue, excluding anticipated wins.

Board and executive committee updates

• Professor Andrew Way appointed to the board, bringing global healthcare experience.

• Victoria Weekes retired from the board in June 2025.

• Board comprises experienced leaders in digital health, finance, and healthcare.